Mondeal (Zolpidem Hemitartrate)

Zolpidem, the active ingredient in Mondeal, is a non‑benzodiazepine hypnotic presented as an oral tablet for oral use. It is prescribed to help adults who have difficulty falling asleep or staying asleep.

GNH USA supplies Mondeal as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Zolpidem is a non‑benzodiazepine hypnotic indicated for the management of insomnia.

- Insomnia: helps initiate and maintain sleep in adults experiencing difficulty falling asleep or staying asleep.

Zolpidem may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Drowsiness or excessive sleepiness - Dizziness or light‑headed feeling - Headache - Nausea or upset stomach - Dry mouth - Short‑term memory impairment

Serious or Rare Side Effects: - Complex sleep behaviours such as sleepwalking or sleep‑driving - Allergic reactions including rash, itching, or swelling - Mood changes, depression, or suicidal thoughts - Severe respiratory depression when combined with other CNS depressants - Hallucinations or psychotic episodes

Before prescribing Mondeal, clinicians should consider several safety measures.

- Assess sleep hygiene: evaluate patient’s sleep habits and non‑pharmacologic measures first. - Evaluate hepatic function: dose adjustment may be needed in severe liver impairment. - Review concomitant CNS depressants: avoid additive sedation with alcohol, opioids, or benzodiazepines. - Monitor for complex sleep behaviours: educate patients about unusual activities during sleep. - Store at ambient temperature below 25°C: keep in the original container, protect from moisture and light.

Zolpidem can interact with other medicines that affect the central nervous system or its metabolism.

Major Interactions (Avoid): - Concurrent use with other CNS depressants (e.g., benzodiazepines, opioids): risk of profound sedation and respiratory depression. - Alcohol: may markedly enhance sedative effects and impair psychomotor performance.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): may increase zolpidem plasma concentrations. - CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce therapeutic effect. - Certain antidepressants (e.g., fluoxetine, sertraline): may increase risk of adverse CNS effects.